CD8A and cancer: Whereas PD-1 inhibition was shown to increase NF-κB activation (28), and CD8+ T-cells are critical mediators of the clinical response to checkpoint-blockade cancer immunotherapies (29, 30), we also show that tumor regression induced by PD-L1 blockade is entirely maintained in Rela-cKO CD8 animals.